Frustration Over English Funding Rejection For Zytiga And A Win For Ledaga
Zyntiga Decision 'Highlights Need For Innovative Pricing Models'
Janssen and UK health technology assessment body NICE are being urged to sit down together and agree a suitable price for using Zytiga as a first-line treatment for advanced prostate cancer.
You may also be interested in...
NICE’s decision today affirming the cost effectiveness of Astellas Pharma’s Xtandi for hormone-sensitive metastatic prostate cancer contrasts with the health technology assessment body’s guidance last month for Janssen’s Erleada.
Limitations in the design of the clinical trials that were carried out for each drug are among the concerns highlighted by the health technology assessment body in two interim guidances that are now out for consultation.
Janssen, the Institute of Cancer Research and patient groups have reacted with disappointment to NICE draft guidance recommending that Zytiga should not be funded by England's National Health Service in a subset of prostate cancer patients. But the existence of an academic study has complicated the situation in an unusual way, and Janssen still hopes to steer a path to reimbursement.